A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

NCT06994650 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy

Interventions

DRUG: HRS9531
DRUG: Placebo

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.